Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.
Cohen
Dan
D
Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. d.cohen@ggz-nhn.nl
Correll
Christoph U
CU
D014150:Antipsychotic Agents / Q000009:adverse effects*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000009:adverse effects*; D003024:Clozapine / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D016883:Diabetic Ketoacidosis / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D003987:Dibenzothiazepines / Q000009:adverse effects*; D006801:Humans; D008403:Mass Screening; D000077152:Olanzapine; D010879:Piperazines / Q000009:adverse effects*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000009:adverse effects*; D012720:Severity of Illness Index
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D015363:Quinolones; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D000068180:Aripiprazole; D003024:Clozapine; D000077152:Olanzapine